Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults
Sponsor: ModernaTX, Inc.
A PHASE1 clinical study on Cytomegalovirus Infection, this trial is completed. The trial is conducted by ModernaTX, Inc. and has accumulated 10 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .